SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

JP Morgan Downgrades Eidos Therapeutics to Neutral, Lowers Price Target of $50

JP Morgan analyst Anupam Rama downgrades Eidos Therapeutics (NASDAQ:EIDX) from Overweight to Neutral and lowers the price target from $58 to $50.

Benzinga · 05/14/2020 09:32

JP Morgan analyst Anupam Rama downgrades Eidos Therapeutics (NASDAQ:EIDX) from Overweight to Neutral and lowers the price target from $58 to $50.